MarketMoodz
Ivonescimab Cuts Death Risk 34% in China Phase 3 (Harmoni‑6)
Akeso and Summit’s PD‑1/VEGF bispecific ivonescimab reduced the risk of death by 34% in the Phase 3 Harmoni‑6 trial versus a PD‑1 inhibitor (tislelizumab) plus chemotherapy, with median overall survival of 27.9 months versus 23.7 months. The result offers an early efficacy signal for the PD‑1/VEGF class in squamous non‑small‑cell lung cancer, but higher bleeding rates and China‑only data leave questions for global regulators and investors.
Key Takeaways
- Ivonescimab + chemotherapy cut risk of death by 34% versus tislelizumab + chemotherapy in Harmoni‑6 (hazard ratio reported by company/press).
- Median overall survival was 27.9 months with ivonescimab versus 23.7 months with the PD‑1 comparator — a four‑month gain.
- Bleeding of any severity occurred in about 25% of patients on ivonescimab; severe bleeding was under 3% versus roughly 1% in the control arm.
- Harmoni‑6 enrolled only Chinese patients; a global Phase 3 (Harmoni‑3) is ongoing with squamous readout expected H2 2026 and non‑squamous in H1 2027.
- Summit Therapeutics licensed rights outside China from Akeso and its stock has jumped roughly 600% over two years amid hopes for a global program.
People Involved
- Suresh RamalingamMedical oncologist, Winship Cancer Institute (commentator)
- Deborah DoroshowOncologist/clinical researcher, Icahn School of Medicine (commentator)
Entities Involved
- AkesoDeveloper of ivonescimab (PD‑1/VEGF bispecific)
- Summit TherapeuticsLicensee of ivonescimab outside China
- Biosing (tislelizumab)PD‑1 inhibitor used in the Harmoni‑6 control arm
- Merck (Keytruda)Market leader PD‑1 competitor in global NSCLC
- Harmoni‑6Phase 3 clinical trial in China (ivonescimab + chemo vs PD‑1 inhibitor + chemo)
MarketMoodz Analysis
For investors, Harmoni‑6’s headline numbers are market‑moving: a 34% reduction in mortality and a median overall survival increase from 23.7 to 27.9 months are material efficacy signals that could reframe the competitive landscape in squamous NSCLC if replicated globally. The result supports the commercial case for a PD‑1/VEGF bispecific — potentially offering a single‑molecule alternative to PD‑1 plus anti‑VEGF combinations — which helps explain Summit’s steep share appreciation after licensing rights outside China. That said, safety data matter: bleeding events occurred in roughly one quarter of patients on ivonescimab and severe bleeding, while still under 3%, was higher than the control (~1%), creating a risk‑benefit calculation regulators and payers will scrutinize.
Context and translation risk are the two thorniest items for investors. Harmoni‑6 was conducted exclusively in China, and regulatory bodies such as the FDA typically want broader, ethnically diverse data before granting approval for global markets. Harmoni‑3 is already enrolling globally, with squamous readout expected in H2 2026 and non‑squamous in H1 2027; those timelines are the next binary events to watch. Historically, PD‑1 plus anti‑angiogenesis approaches have shown activity in NSCLC but have also carried bleeding or vascular safety signals — squamous histology has been particularly sensitive to hemorrhage with VEGF pathway drugs — so confirmatory safety data will be critical for labeling, clinician uptake, and commercial positioning against incumbents like Keytruda and bevacizumab‑based regimens.
What to monitor next: the full Harmoni‑6 dataset and independent verification from company filings or peer‑reviewed publication; Harmoni‑3 enrollment progress and interim readouts; detailed adverse‑event breakdowns (timing, grade, management); and any regulatory guidance or filing plans from Akeso and Summit. Also watch pricing and payer conversations once global data arrive — a bispecific that meaningfully improves survival could command premium pricing, but safety concerns and competition from established PD‑1 regimens will shape uptake and revenue forecasts.
Source: Original Article